741910
Last Update Posted: 2023-11-18
Recruiting has ended
All Genders accepted | 18 Years + |
15 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Extension Study of Semapimod 60 mg IV x 3 Days
Study CNI-1493-CD06 is an open, single-arm extension studies to CD03 and CD05. CDAI is the only efficacy measure assessed in this study. The safety of multiple courses of semapimod is to be determined by the incidence of clinical and laboratory adverse events.
Eligibility
Relevant conditions:
Crohn's Disease
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov